002462 Cachet Pharmaceutical
- 10.43
- -0.10-0.95%
Cachet Pharmaceutical News
Kashitang: 2024 Semi-Annual Report
Jiashitang: Summary of the 2024 Semi-Annual Report
Cachet Pharmaceutical (002462.SZ): net income of 0.168 billion yuan in the first half of the year, a year-on-year increase of 8.19%.
Cachet Pharmaceutical (002462.SZ) announced its interim report for the first half of 2024, with a reported revenue of 12.839 billion yuan, a year-on-year decrease of 13.70%; net income attributable to the shareholders of the listed company was 0.168 billion yuan, a year-on-year increase of 8.19%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.107 billion yuan, a year-on-year decrease of 28.38%; basic earnings per share were 0.58 yuan.
Cachet Pharmaceutical (002462.SZ) announced its performance for the first half of the year, with a net income of 0.168 billion yuan, an 8.19% increase.
Cachet Pharmaceutical (002462.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue of 1...
Cachet Pharmaceutical Chairman Resigns
Cachet Pharmaceutical (002462.SZ) announced the resignation of its director and chairman of the board, Xu Wenli.
Cachet Pharmaceutical (002462.SZ) announced that its chairman, Xu Wenli, resigned from the company due to internal work adjustments within the group in a recent announcement.
Cachet Pharmaceutical (002462.SZ) will distribute a dividend of 2.6 yuan per share with a total of 10 dividends for the year 2023. The date for recording the equity is June 26th.
Cachet Pharmaceutical (002462.SZ) announced that the annual equity distribution plan for 2023 is based on the current total share capital of 291,707,120 shares, distributing RMB 2.60 in cash (including tax) per 10 shares to all shareholders. The registration date is June 26, 2024 and the ex-right and ex-dividend date is June 27, 2024.
Cachet Pharmaceutical's (SZSE:002462) Soft Earnings Are Actually Better Than They Appear
Jiashitang (002462.SZ) reported 2023 annual results, net profit of 250 million yuan, a year-on-year decrease of 15.79%
Jiashitang (002462.SZ) released its 2023 annual report. The company achieved 299 operating income during the reporting period...
Jiashitang (002462.SZ): Zhao Baofu no longer holds the position of director
Jiashitang (002462.SZ) announced that the company recently received information from the shareholder China Everbright Group Co., Ltd. about the company...
Benign Growth For Cachet Pharmaceutical Co., Ltd. (SZSE:002462) Underpins Stock's 30% Plummet
The Returns On Capital At Cachet Pharmaceutical (SZSE:002462) Don't Inspire Confidence
[Instant Analysis of BT Financial Report] Jiashitang's 2023 Interim Report: Operating income has increased steadily, net cash flow has increased dramatically
The 2023 interim report of Jiashitang (stock code: 002462) has been published. This article will interpret its financial data from the perspective of a financial analyst. First, let's take a look at Jiashitang's revenue. Revenue for the reporting period was 14,877,717,780.55 yuan, an increase of 17.09% compared to 12,706,434,721.05 yuan for the same period last year. This is mainly due to the increase in revenue from the pharmaceutical wholesale business. However, the net profit attributable to shareholders of listed companies during the reporting period was 155,489,204.07 yuan, compared with 169 in the same period last year.
Investors Can Find Comfort In Cachet Pharmaceutical's (SZSE:002462) Earnings Quality
Jiashitang (002462.SZ): Net profit fell 8.26% in the first half of the year to 155 million yuan
Glonghui, August 30, 丨 Jiashitang (002462.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 14.878 billion yuan, up 17.09% year on year; net profit attributable to shareholders of listed companies was 155 million yuan, down 8.26% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149 million yuan, down 7.87% year on year; basic earnings per share.
Is Cachet Pharmaceutical (SZSE:002462) Using Too Much Debt?
Jiashitang (002462.SZ): Currently, all pharmacy chains are directly managed, and no pharmacy franchise matters have been launched
GLONGHUY July 5: Some investors asked Jiashitang (002462.SZ), “Can the company join the pharmacy chain?” In response, Carshitang said that currently all of the company's pharmacy chains are directly managed, and no pharmacy franchise matters have yet been initiated.
Slowing Rates Of Return At Cachet Pharmaceutical (SZSE:002462) Leave Little Room For Excitement
Positive Earnings Growth Hasn't Been Enough to Get Cachet Pharmaceutical (SZSE:002462) Shareholders a Favorable Return Over the Last Five Years
Can Mixed Fundamentals Have A Negative Impact on Cachet Pharmaceutical Co., Ltd. (SZSE:002462) Current Share Price Momentum?
Analysis
Price Target
No Data
No Data